Kelun-Biotech Raises $250 Million in Largest Hong Kong Biopharma Follow-On Offering in 12 Months
Kelun-Biotech successfully completed a $250 million share placement on June 5, 2025, representing the largest follow-on offering in Hong Kong's biopharma sector over the past 12 months.
Kelun-Biotech's SKB445 ADC Receives NMPA Approval for Advanced Solid Tumor Trials
Kelun-Biotech's SKB445, a novel antibody-drug conjugate (ADC), has been approved by China's NMPA for clinical trials in advanced solid tumors.